Skip to main content
. 2021 Aug 2;3(1):vdab103. doi: 10.1093/noajnl/vdab103

Figure 5.

Figure 5.

In vitro effect of IDH mutant-specific inhibitors on IDHmt glioma cultures. (A) Percentage of D2-HG in IDHmt (N = 6) and IDHwt (N = 2) cell cultures treated with increasing concentrations of IDH-mutant specific inhibitor AGI-5198 compared to DMSO-controls. Each datapoint represents a single measurement. (B) Mean average survival of IDHmt (N = 6) and IDHwt (N = 2) cultures treated with increasing concentrations of BAY-1438032 or AGI-5198. Data are presented as mean percentage survival ± SD. Each culture was tested in three technical replicates. (C) Mean doubling times of IDHmt (N = 6) and IDHwt (N = 2) cell cultures, cultured with and without 10 µM IDH mutant-specific inhibitor AGI-5198. Error bars represent standard deviations over three consecutive passages. (*P < .05, paired T-test). Three technical replicates were used for each culture and each time point. (D) Heatmap showing unsupervised cluster analysis of RNA expression of IDHmt (N = 8) and IDHwt (N = 4) glioma cultures, cultured with and without IDH mutant-specific inhibitor AGI-5198 for seven days. Unsupervised clustering was performed on the 1000 most variably expressed genes. The heatmap was scaled by row.